Celldex Therapeutics Inc. (NASDAQ:CLDX) saw an upside of 1.17% to close Friday at $30.19 after adding $0.35 on the day. The 5-day average trading volume is 396,100 shares of the company’s common stock. It has gained $31.51 in the past week and touched a new high 3 times within the past 5 days. An average of 383,625 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 449,042.
CLDX’s 1-month performance is -18.49% or -$6.24 on its low of $27.52 reached on 08/09/23. The company’s shares have touched a 52-week low of $27.01 and high of $48.40, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, CLDX has lost -32.26% or -$14.38 and has reached a new high 4 times. However, the current price is down -37.62% from the 52-week high price.
Insider Transactions
CLDX stock investors last saw insider trading activity on Dec 07.KELER TIBOR (EXECUTIVE VP & CSO) most recently sold 16,860 shares at $36.93 per share on Dec 07. This transaction cost the insider $622,611.
Valuation Metrics
CLDX stock has a beta of 2.15. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 427.33 while the price-to-book (PB) in the most recent quarter is 5.14.
Celldex Therapeutics Inc.’s quick ratio for the period ended June 29 was 16.90, with the current ratio over the same period at 16.90. The trailing 12-month EBITDA margin is -4484.34%. The firm’s gross profit as reported stood at $117.59 million against revenue of $2.36 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -18.03% to -$30.5 million, while revenue of -$29.36 million was 3.74% off the previous quarter. Analysts expected CLDX to announce -$0.67 per share in earnings in its latest quarter, but it posted -$0.65, representing a 3.00% surprise. EBITDA for the quarter stood at more than -$33.61 million. CLDX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 21.77 million, with total debt at $3.25 million. Shareholders hold equity totaling $47.26 million.
Let’s look briefly at Celldex Therapeutics Inc. (CLDX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 30.52% to suggest the stock is trending Neutral, with historical volatility in this time period at 40.57%.
The stock’s 5-day moving average is $30.54, reflecting a -0.13% or -$0.04 change from its current price. CLDX is currently trading -17.08% above its 20-day SMA, -14.23% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -14.31% and SMA200 by-14.06%.
Stochastic %K and %D was 31.43% and 35.10% and the average true range (ATR) pointed at 1.46. The RSI (14) points at 32.89%, while the 14-day stochastic is at 33.04% with the period’s ATR at 1.49. The stock’s 9-day MACD Oscillator is pointing at -0.65 and -1.77 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Celldex Therapeutics Inc. (NASDAQ: CLDX), Jefferies launched coverage with a Buy rating. Analysts offering their rating for CLDX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CLDX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is CLDX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $54.00 and a high of $73.00, with their median price target at $66.50. Looking at these predictions, the average price target given by analysts is for Celldex Therapeutics Inc. (CLDX) stock is $66.00.
